大疱性类天疱疮临床评估指标的研究进展

中华皮肤科杂志 ›› 2016, Vol. 49 ›› Issue (1): 65-68.

大疱性类天疱疮临床评估指标的研究进展

刘艺迪¹,左亚刚²,李丽³

1. 中国医学科学院北京协和医学院北京协和医院皮肤科
2. 中国医学科学院北京协和医学院北京协和医院
3. 北京协和医院皮肤科

收稿日期:2015-07-17 修回日期:2015-07-28 出版日期:2016-01-15 发布日期:2015-12-31
通讯作者: 李丽 E-mail:li.lilievert@gmail.com
基金资助:
国家自然科学基金;北京市自然科学基金

Clinical measures of bullous pemphigoid

Yi-Di LIU¹,Ya-gang ZUO¹,

Received:2015-07-17 Revised:2015-07-28 Online:2016-01-15 Published:2015-12-31

摘要/Abstract

摘要：

大疱性类天疱疮是一类自身免疫性疱病。针对自身免疫性大疱病，有专门的评分指标用以评估病情的严重程度和对治疗的反应。常用的评价指标有自身免疫性疱病严重程度评分，专门针对大疱性类天疱疮的大疱性类天疱疮疾病面积指数评分，以及其他的一些评分方式。自身免疫性大疱病严重程度评分已经经过了效度检验，广泛地应用在寻常型天疱疮和其他一些自身免疫性疱病的评估中。大疱性类天疱疮疾病面积指数评分尚处于检验的过程中，应用该评分的临床试验较少。上述两种评分方式均对全身的皮肤、黏膜皮损情况，主观瘙痒程度进行了评分。

Abstract:

Liu Yidi, Zuo Yagang, Li Li Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China Corresponding author： Li Li, Email: lilipumch2007@sina.com 【Abstract】 Bullous pemphigoid （BP） is a group of autoimmune blistering skin diseases. There are special measures for the assessment of disease severity and therapeutic response in autoimmune bullous skin diseases. Common scoring indexes include autoimmune bullous skin disorder intensity score （ABSIS）, bullous pemphigoid disease area index （BPDAI）, and so on. ABSIS has been validated, and is widely applied in evaluation of pemphigus vulgaris and other autoimmune blistering diseases. BPDAI is still in the process of verification, and has been applied in only a few clinical trials. The evaluation of diseases by ABSIS and BPDAI is both based on a global assessment of skin and mucosal lesions, and degree of subjective pruritus.

刘艺迪左亚刚李丽. 大疱性类天疱疮临床评估指标的研究进展[J]. 中华皮肤科杂志, 2016, 49(1): 65-68.doi:

Yi-Di LIU Ya-gang ZUO. Clinical measures of bullous pemphigoid[J]. Chinese Journal of Dermatology, 2016, 49(1): 65-68.doi:

参考文献 16

［1］	Charneux J, Lorin J, Vitry F, et al. Usefulness of BP230 and BP180⁃NC16a enzyme⁃linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients［J］. Arch Dermatol, 2011,147（3）: 286⁃291. DOI: 10.1001/archdermatol.2011.23.
［2］	Feng S, Wu Q, Jin P, et al. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid［J］. Int J Dermatol, 2008, 47（3）: 225⁃228. DOI: 10.1111/j.1365⁃4632.2008.03473.x.
［3］	Pfutze M, Niedermeier A, Hertl M, et al. Introducing a novel autoimmune bullous skin disorder intensity score （ABSIS） in pemphigus［J］. Eur J Dermatol, 2007,17（1）: 4⁃11. DOI: 10.1684/ejd.2007.0090.
［4］	Daniel BS, Hertl M, Werth VP, et al. Severity score indexes for blistering diseases［J］. Clin Dermatol, 2012, 30（1）: 108⁃113. DOI:10.1016/j.clindermatol.2011.03.017.
［5］	Rahbar Z, Daneshpazhooh M, Mirshams⁃Shahshahani M, et al. Pemphigus disease activity measurements: pemphigus disease area index, autoimmune bullous skin disorder intensity score, and pemphigus vulgaris activity score［J］. JAMA Dermatol, 2014, 150（3）: 266⁃272. DOI: 10.1001/jamadermatol.2013.8175.
［6］	张洁尘, 冯素英, 王宝玺. 天疱疮疗效评估的研究进展［J］. 中华皮肤科杂志, 2012, 45（1）: 60⁃62. DOI: 10.3760/cma.j.issn.0412⁃4030.2012.01.028.
	Zhang JC, Feng SY, Wang BX. Clinical outcome measures for pemphigus: an update［J］. Chin J Dermatol, 2012, 45（1）: 60⁃62. DOI: 10.3760/cma.j.issn.0412⁃4030.2012.01.028.
［7］	Murrell DF, Daniel BS, Joly P, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts［J］. J Am Acad Dermatol, 2012, 66（3）: 479⁃485. DOI: 10.1016/j.jaad.2011.06.032.
［8］	Patsatsi A, Kyriakou A, Pavlitou⁃Tsiontsi A, et al. Association of autoantibodies to BP180 with disease activity in Greek patients with bullous pemphigoid［J］. Clin Dev Immunol, 2012, 2012: 854795. DOI: 10.1155/2012/854795.
［9］	Zhao CY, Murrell DF. Outcome measures for autoimmune blistering diseases［J］. J Dermatol, 2015, 42（1）: 31⁃36. DOI: 10.1111/1346⁃8138.12711.
［10］	Lévy⁃Sitbon C, Barbe C, Plee J, et al. Assessment of bullous pemphigoid disease area index during treatment: a prospective study of 30 patients［J］. Dermatology, 2014, 229（2）: 116⁃122. DOI: 10.1159/000362717.
［11］	Lee EH, Kim YH, Kim S, et al. Usefulness of enzyme⁃linked immunosorbent assay using recombinant BP180 and BP230 for serodiagnosis and monitoring disease activity of bullous pemphigoid［J］. Ann Dermatol, 2012, 24（1）: 45⁃55. DOI: 10.5021/ad.2012.24.1.45.
［12］	Herbst A, Bystryn JC. Patterns of remission in pemphigus vulgaris［J］. J Am Acad Dermatol, 2000, 42（3）: 422⁃427.
［13］	赵邑, 刘晶, 姜薇, 等. 大疱性类天疱疮患者血清鳞状细胞癌抗原的检测［J］. 中国皮肤性病学杂志, 2010, 24（8）: 715⁃717.
	Zhao Y, Liu J, Jiang W, et al. Serum squamous cell carcinoma antigen in bullous pemphigoid patients［J］. Chin J DermVenereol, 2010, 24（8）: 715⁃717.
［14］	Tsuji⁃Abe Y, Akiyama M, Yamanaka Y, et al. Correlation of clinical severity and ELISA indices for the NC16A domain of BP180 measured using BP180 ELISA kit in bullous pemphigoid［J］. J Dermatol Sci, 2005, 37（3）: 145⁃149. DOI: 10.1016/j.jdermsci.2004.10.007.
［15］	金岩, 付海军, 翁孟武. HLA⁃Ⅱ类基因与大疱性类天疱疮的相关性研究［J］. 中华皮肤科杂志, 2003, 36（7）: 368⁃371. DOI:10.3760/j.issn:0412⁃4030.2003.07.002.
	Jin Y, Fu HJ, Weng MW. Association of HLA⁃DRB1, DQA1, DQB1 in patients with bullous pemphigoid［J］. Chin J Dermatol, 2003, 36（7）: 368⁃371. DOI: 10.3760/j.issn:0412⁃4030.2003.07.002.
［16］	Schmidt E, Obe K, Brocker EB, et al. Serum levels of auto⁃antibodies to BP180 correlate with disease activity in patients with bullous pemphigoid［J］. Arch Dermatol, 2000, 136（2）: 174⁃178. DOI: 10.1001/archderm.136.2.174.